

Global e·dentity™ receives first U.S. Patent for Covid-19 detection

Wilmington, DE –Dec 29, 2020 — Global e·dentity™ Inc, the biometric identification startup, has received its fourth U.S. Patent and Trade Office (PTO) patent number US 10,880,303 REAL-TIME COVID-19 OUTBREAK IDENTIFICATION WITH NON-INVASIVE, INTERNAL IMAGING FOR DUAL BIOMETRIC AUTHENTICATION AND BIOMETRIC HEALTH MONITORING.

Global e·dentity's™ newest patent is the first U.S. patent (and the first identified technology in the world) to use biometric scanning to identify individuals who are asymptomatic or pre-symptomatic for Covid-19 or SARS. This latest Global e·dentity™ patent enables organizations or countries using the company's market-leading biometric identification technology to scan for both 100% personal identification and Covid-19 or SARS. The company's fourth patent is a continuation of Multimodal Biometric and Digital Identity original patent US 10,135,822 issued in November 2018, which recognizes the Global e·dentity™ team's groundbreaking development of advanced multi-modal biometric identification/health technology.

“This new patent is a serious game-changer as the world now understands the emergence of both Identity and health multi-modal biometrics as one,” says Global e·dentity™ Founder Dr. Robert Adams. “Countries that implement our biometric identification scanning technology will gain a competitive advantage in being able to open their economies while easily identifying travelers infected with Covid-19 or other health issues during the next pandemic. Ours is the first patent in the U.S. to fully identify, with a near hundred percent accuracy, those with biometric markers of Covid-19 or SARS who are asymptomatic or pre-symptomatic.”

This newest patent broadens Global e·dentity's™ original patent “822” to cover additional non-invasive ways of validating individual identity and health. Global e·dentity's™ health screening can be accomplished during regular biometric identification screening at locations like border crossings or

airports. The technology uses near-infrared (NIR) scanning, linked to multi-modal biometric identification that is unique to each individual; the same technology used to scan the vascular network for identity can also be used to identify biometric markers of those who may be infected with Covid-19 and are asymptomatic. As noted in the newest patent, those few individuals whose biometric scan indicates the markers of the infection will need to undergo medical-grade OCR/NAT testing to confirm Global e-identity's™ initial NIR/chemosensory scan.

“Dorian Cartwright and Kym Moore at the Law offices of Dorian Cartwright have been amazing to work with since we started the company,” says Adams. “This is the fourth patent issued for our technology in two years, and we will file six more multi-modal biometrics/health continuation patents in 2021 on behalf of our client.”

Global e-identity™ Inc. is a leading provider of multi-factor bio-metric, digital identity solutions, and now health biometrics is registered as a corporation in Delaware. The company anticipates using millions of its biometric scanners at airports and border crossing locations for both personal identification biometrics and early identification of Covid-19 and other health issues. Global e-identity™ is currently working with preferred technology vendors in the development and worldwide deployment of these systems.

For more information, visit www.globaledentity.com. Global e-identity™ and product(s) are either registered trademarks or trademarks of Global e-identity™ Inc in the United States and/or other countries. *For more information, press only: Sophia Miller: somiller@globaledentity.com*